ERBB2 and gastroesophageal junction adenocarcinoma: However, the phase 3 ATTRACTION-4 trial demonstrated that first-line nivolumab plus oxaliplatin-based chemotherapy resulted in a significant improvement in PFS, but not OS, in Asian patients with untreated, HER2-negative, unresectable advanced or recurrent G/GEJ adenocarcinoma with a tumor proportion score (TPS) of ≥1 (114 of 724; 15.7%) [22].